AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: methotrexate placebo orally, Week 17-28
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 28 weeks
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 28 weeks
Study NCT03988738 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Social Media Publications
Description: Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
Study NCT03450759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (fastvrate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Study NCT03450759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (Int. rate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Study NCT04508686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, camrelizumab
Description: This is a single-arm study with all patients receiving these two drugs.
Study NCT00356109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 6 months
Study NCT00356109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable insulin
Description: patient specific dose, injected, before meals, 6 months
Study NCT00356109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 6 months
Study NCT00356109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 6 months
Study NCT03782181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration platform
Description: A neuromuscular treatment using a rotational whole body vibration platform.
Study NCT04284683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRINK - Water, Protein, Fat, Carbohydrate
Description: Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
Study NCT02676557 — intervention group
Intervention type: DEVICE
Intervention: Exposed to the high pressure during the surgery
Study NCT03875469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centargo injector (BPI 1000045)
Description: Contrast-enhanced computer tomography conducted with Centargo injector
Study NCT03875469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellant MP injector
Description: Contrast-enhanced computer tomography conducted with Stellant MP injector
Study NCT01510821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Maquet Vasoshield Pressure-limiting syringe on SVG
Description: Use of Maquet Vasoshield Pressure-limiting syringe on SVG
Study NCT01510821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of non-regulated syringe on SVG
Description: Use of non-regulated syringe on SVG
Study NCT01921517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Magnitude Mechanical Stimulation
Description: Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
Study NCT01921517 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Low Magnitude Mechanical Stimulation
Description: Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
Study NCT00500448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
Study NCT01754324 — intervention group
Intervention type: DRUG
Intervention: Methadone
Description: The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
Study NCT04221269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment as Usual
Description: Routine community care plus assessment feedback reports to clinicians.
Study NCT03988738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Publications
Description: Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
Study NCT02579135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Sex
Description: Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
Study NCT02579135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Growth Mindsets
Description: Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
Study NCT02812940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: GvHD prophylaxis
Study NCT01921153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy meal plates and trays
Description: The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
Study NCT04221269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Routine community care plus assessment feedback reports to clinicians.
Study NCT04221269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Long-term with Active Suicide Program for Schizophrenia
Description: Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
Study NCT02963155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT01301040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cyclophosphamide, docetaxel
Description: * Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Study NCT04646291 — intervention group
Intervention type: DEVICE
Intervention: Insemination with the Mosie Baby Kit
Description: The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
Study NCT02179567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
Study NCT02179567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
Study NCT02687438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steroid-releasing sinus implant
Description: PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
Study NCT02687438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-op standard of care
Description: post-op standard of care including debridement, irrigation, and/or topical steroids
Study NCT03461159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of H-reflexes
Description: Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
Study NCT03461159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of motor evoked potentials
Description: Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
Study NCT04091061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 100 mg
Description: PF-06865571 in 100 mg oral tablet will be administered on Day 1
Study NCT00742326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg/daily
Study NCT00988104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
Study NCT00988104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
Study NCT00775762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Aspirin (75-100 mg)die for three months
Study NCT00775762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel (75mg) die for three months
Study NCT00742326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily
Study NCT01693900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-operative Ultrasound FICB Group
Description: Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
Study NCT01693900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative FICB Group
Description: Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
Study NCT00310557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study NCT02338453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Attention Bias Modification Treatment
Description: Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
Study NCT02338453 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Bias Modification Treatment
Description: the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
Study NCT00775762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel plus aspirin
Description: clopidogrel 75 mg die plus aspirin 75-100 mg for three months
Study NCT00983645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
Study NCT00825539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Study NCT00825539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02712749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound with Binaural Beats
Description: Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
Study NCT02712749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sound without Binaural Beats
Description: Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
Study NCT00657462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
Study NCT00657462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminders
Description: Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
Study NCT03530748 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular therapy and Imaging Acquisition
Description: 1. Endovascular repair for renal artery stenosis;~2. Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney
Study NCT02780518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo
Description: Applying high flow nasal oxygen
Study NCT02650713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
Study NCT00983645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Cyclosporine (Neoral) starting dose 3mg/kg PO BID
Study NCT01676103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: Tyrosine supplementation (500 mg 2 x daily) for 7 days
Study NCT01676103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:Sugar Pill
Description: Placebo sugar pills (2x daily
Study NCT03905837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous or paravertebral lidocaine
Study NCT03905837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous remifentanil
Study NCT01618786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmartCell flooring
Description: SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
Study NCT01618786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plywood flooring
Description: Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
Study NCT01823471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of I-scan in the detection of polyps in HNPCC
Description: Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
Study NCT01823471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The use of I-scan in the detection of polyps in HNPCC
Description: Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
Study NCT02114619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of I-131
Description: We wil administer 100 micro currie of iodine per thyroid gram
Study NCT02114619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose
Description: We will administer 150 micro currie of iodine per thyroid gram
Study NCT02114619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose
Description: We will administer 200 micro currie of iodine per thyroid gram
Study NCT02630563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
Study NCT02630563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine will be administered as per center practice.
Study NCT02630563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
Study NCT04812184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tape Face Mask
Description: Adding tape to face mask
Study NCT02104076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution® Biliary Stent-Fully Covered
Description: Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
Study NCT01649882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US ETT (ultrasound endotracheal tube)
Description: Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
Study NCT02558842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Strategy
Description: Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit.
Study NCT00379561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSA-Activated PSA-PAH1
Study NCT01799447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early intervention
Description: Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
Study NCT01495052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: organic naked oat with whole germ (ONOG)
Description: The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
Study NCT01676051 — intervention group
Intervention type: OTHER
Intervention: Skin culture
Description: Culture swab used to culture skin adjacent to incision
Study NCT02195635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 500 mg telotristat etiprate
Study NCT02195635 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telotristat etiprate
Description: 500 mg telotristat etiprate
Study NCT02195635 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide acetate
Description: 200 µg octreotide acetate three times daily